The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
Pyrilutamide's effect on sebum production and scalp inflammation is unclear, with users noting no significant changes. Isotretinoin is mentioned as effective for reducing sebum, while Dutasteride and various shampoos have limited impact on oiliness and seborrheic dermatitis.
GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.
Scalp inflammation can cause hair thinning and may be related to diet, infections, or conditions like psoriasis. Treatments suggested include using Nizoral shampoo and checking vitamin levels.
The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.
The conversation discusses the effectiveness of pyrithione zinc and GT20029 for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Panax ginseng, specifically a ginsenoside-enriched formulation, is suggested as a potential hair growth treatment alongside finasteride and minoxidil. The user is considering trying panax ginseng despite limited availability and evidence.
A user is considering starting spironolactone for androgenetic alopecia but is concerned about stopping it before pregnancy. Another user suggests trying topical treatments as an alternative.
Creating a propylene glycol-free Minoxidil and Tretinoin solution to reduce skin irritation and enhance effectiveness. An emulsifier like lecithin can help mix Tretinoin properly, and Minoxidil foam is an alternative without propylene glycol.
A user reported significant hair improvement using oral minoxidil, Rogaine 5%, and spironolactone but experienced worsening PMS. They seek advice on managing the PMS symptoms.
Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.
The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.
After a second session of Platelet-Rich Plasma (PRP) treatment for hair regrowth, the user is experiencing increased shedding of thick and dark hairs and is concerned about whether this is temporary. They are seeking others' experiences with PRP, specifically regarding the duration of shedding and eventual positive outcomes.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
A user's experience with Pyrilutamide, which they have been taking for 3 months to treat their aggressive male pattern baldness. The user reported that the medication decreased shedding and was hopeful it would work as advertised.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
The user is experiencing chest sensitivity and muscle ache after using topical finasteride for a month and is concerned about potential gynecomastia. They are considering asking their doctor for blood work to check estrogen levels and are questioning whether to stop using finasteride.
The conversation discusses a 24-year-old Korean man's progress with hair loss treatments over 8-9 months, with specific treatments not mentioned due to redacted information. Users are commenting on the effectiveness and inquiring if Asians have better results with hair loss treatments.
The user experienced hair repigmentation and attributes improvements in hair and overall health to a carnivore diet, Boron, and Selenium supplementation. They stopped using finasteride after 20 years, noticed increased testosterone and libido, and observed hair regrowth with RU58841.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
The conversation discusses androgenetic alopecia (AGA) and questions why treatments focus on lowering DHT levels instead of building resistance to it. It also touches on hair transplantation techniques using body hair.
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
The user has been treating hair loss with finasteride, dutasteride, oral minoxidil, and pyrilutamide for several years without success and is experiencing an inflamed scalp, possibly due to seborrheic dermatitis. They are seeking advice on additional treatments after these methods failed to improve their condition.